Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79139.691.493%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Xenon Pharmaceuticals Inc

XENENASDAQ
Trade with Public
Trade with Public
$59.75
-0.65-1.08%
At close: Sep 4, 5:00 PM EST
$59.75
N/A
After Hours: Sep 4, 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Xenon Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Xenon Pharmaceuticals (XENE).

Price Target Range — 13 Quarters

Analyst Consensus — 17 Analysts

17Buy
Consensus RatingBuy# Analysts17Avg. Consensus PT$66Upside to Avg. PT+11.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 7, 2026RBC CapitalBrian AbrahamsPT CutOutperform$82→$81
May 27, 2026JP MorganTessa RomeroPT RaiseOverweight$80→$82
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $81

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $82 to $81.
Benzinga Newsdesk

Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out

Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahead of key epilepsy trial data.
Vandana Singh

PRO
JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $82

JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $80 to $82.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $80

JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $77 to $80.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $82

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $80 to $82.
Benzinga Newsdesk

PRO
Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $78

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $80 to $78.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved